ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
By Dr. Matthew Watson
SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 3:00 p.m. ET.
See original here:
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer
By Dr. Matthew Watson
SALINAS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces the appointment of Jamie Schniedwind as Chief Financial Officer of the Company, effective February 16, 2024.
Read more here:
Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With…
By Dr. Matthew Watson
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) an Orphan-Drug Designation (ODD) following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. This follows the Rare Pediatric Disease Designation (RPDD) granted by FDA last month.
Here is the original post:
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With...
CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant
By Dr. Matthew Watson
CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant
Read more from the original source:
CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
By Dr. Matthew Watson
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
See the original post:
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
By Dr. Matthew Watson
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Read the original:
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
3D printing and material processing combined to create artificial bone – Optics.org
By daniellenierenberg
3D printing and material processing combined to create artificial bone Optics.org
Read the rest here:
3D printing and material processing combined to create artificial bone - Optics.org
City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia … – StreetInsider.com
By daniellenierenberg
City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia ... StreetInsider.com
See the original post:
City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia ... - StreetInsider.com
Hematopoietic Stem Cells and Their Role in Development and Disease Therapy – The Scientist
By daniellenierenberg
Hematopoietic Stem Cells and Their Role in Development and Disease Therapy The Scientist
Read the rest here:
Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist
Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure – Phys.org
By daniellenierenberg
Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure Phys.org
Read this article:
Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure - Phys.org
Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant… – The Sun
By daniellenierenberg
Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant... The Sun
Excerpt from:
Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant... - The Sun
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual…
By Dr. Matthew Watson
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Read the original here:
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual...
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
By Dr. Matthew Watson
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
Go here to read the rest:
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Virbac : Declaration of the number of shares and voting rights 01/2024
By Dr. Matthew Watson
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS
Go here to see the original:
Virbac : Declaration of the number of shares and voting rights 01/2024
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 33,750 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
By Dr. Matthew Watson
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET.
Follow this link:
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each case with a grant date of February 1, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
See the article here:
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Regeneron Announces Investor Conference Presentations
By Dr. Matthew Watson
TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
See the original post:
Regeneron Announces Investor Conference Presentations
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
By Dr. Matthew Watson
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
See the article here:
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Sutro Biopharma to Participate in Upcoming Investor Conferences
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
See the rest here:
Sutro Biopharma to Participate in Upcoming Investor Conferences